Quest LaboratoriesShare price, financial results, shareholding and management

NSE Emerge · QUESTLABGeneric medicinesListed 23 May 2024IPO ₹97
questlabltd.com ↗Live price on NSE ↗ISIN INE0TNW01017 · Lot 1,200 shares · ₹1.07 lakh
₹89.10
+0.10% on the day
Close · 18 Nov 2026
Valuation
Market cap
₹146 cr
Stock P/E
9.7peers 19.8
Book value
₹59.1
Price to book
1.51
EV / operating profit
8.4
Market cap to sales
1.31
Returns and growth
ROCE · FY26
18.4%
ROE · FY26
16.8%
ROE, 3-year average
28.9%
Operating margin · FY26
16.3%peers 12.8%
Sales growth, 3 years
21.7%
Profit growth, 3 years
44.3%
Safety
Debt to equity
0.08peers 0.48
Borrowings
₹7.9 cr
Interest cover
10.8×
Cash from business / op. profit
-59%
Debtor days
118
Pledged
0.00%
Ownership and share
Promoter holding
66.78%
Change in promoter holding
0.00 pts
Shareholders
911
52-week high / low
₹153 / ₹69
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Quest Laboratories share price chart

₹89.10+0.91% 1 year

Close on 18 Nov 2026 · +0.06% on the day · Vol 2,400

Daily prices to 18 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 18 Nov 2026

1 month
-1.2%
3 months
+0.1%
6 months
-18.0%
1 year
+0.9%
Since IPO
-8.1%
Traded a day, 20 days
₹0.10 cr
Taken for delivery
86%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+8%+11%
3 years, a year+22%+44%
Latest half, H2 FY26+3%+24%

About Quest Laboratories: business, products and customers

Quest Laboratories makes everyday generic medicines such as tablets, syrups, oral rehydration salts and ointments at its plant in Pithampur, Madhya Pradesh, mostly for government health programmes. Its shares trade on NSE Emerge.

Quest Laboratories has one factory at Pithampur near Indore, where it makes several hundred generic formulations: antibiotics, painkillers, antimalarials, diabetes and allergy medicines, vitamins, oral rehydration salts, creams and antiseptic liquids. Tablets bring in most of the money. It reaches buyers in four ways: bids in state and central government tenders for medicines given out free, a franchise model where regional partners market its products, white label manufacturing for other drug companies, and exports through buyers abroad.

Government tenders give bulk orders and fixed volumes, but the price is set by bidding, so margins rest on keeping costs low. Government buyers are also slow payers, and the company holds large stocks of medicines and materials, so a big part of its money sits in receivables and inventory. The plant runs close to full on syrups, tablets and oral salts, while dry syrups and external liquids are used far less.

Read more about the business

The offer document compares it with Beta Drugs, Alpa Laboratories and Zenith Drugs, other listed makers of generic formulations. The company is building an injectable section for vials, ampoules and dry injections, aimed at cancer medicines and export markets, and is setting up a capsule line. In September 2026 it began an advisory tie up with Niraga Capitals to look at export markets, partnerships, fund raising and acquisitions.

From the offer document, the FY26 annual report, the July 2025 investor presentation and the company's September 2026 exchange announcements.

Read the deeper study ↓

In its favour

  • Sales have grown fast: 22% a year over three years.
  • It has little debt for its size: debt to equity 0.08.
  • The promoters own a large part of the company: 66.78%.

To watch

  • Delivery of the ₹39.7 cr order book, including ₹10.7 cr of export orders for the third quarter of FY27 (Exchange announcement, 28 Sep 2026).
  • Completion of the injectable section for vials, ampoules and dry injections (Investor presentation, Jul 2025, p.4).
  • Whether the large stock built up at March 2026 turns into sales and cash (Annual report FY26, p.55).
  • Any fund raising, partnership or acquisition that comes out of the Niraga Capitals advisory tie up (Exchange announcement, 28 Sep 2026).
  • It paid no dividend in the past year.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Quest Laboratories revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown fast. Last year profit grew roughly in step with sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150Sales, FY21: 30 ₹ cr30Net profit, FY21: 1 ₹ cr1FY21Sales, FY22: 59 ₹ cr59Net profit, FY22: 4 ₹ cr4FY22Sales, FY23: 62 ₹ cr62Net profit, FY23: 5 ₹ cr5FY23Sales, FY24: 83 ₹ cr83Net profit, FY24: 10 ₹ cr10FY24Sales, FY25: 104 ₹ cr104Net profit, FY25: 13.6 ₹ cr13.6FY25Sales, FY26: 112 ₹ cr112Net profit, FY26: 15 ₹ cr15FY26
The latest halves, ₹ crore
SalesNet profit
020406080Sales, H2FY25: 61.3 ₹ cr61.3Net profit, H2FY25: 5.6 ₹ cr5.6H2FY25Sales, H1FY26: 48.8 ₹ cr48.8Net profit, H1FY26: 8.1 ₹ cr8.1H1FY26Sales, H2FY26: 63 ₹ cr63Net profit, H2FY26: 6.9 ₹ cr6.9H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Quest Laboratories half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H2FY25H1FY26H2FY26
Sales61.2948.8063.02
Expenses56.6741.6151.97
Operating profit4.627.2011.05
OPM7.5%14.8%17.5%
Interest0.401.220.63
Depreciation0.340.410.41
Profit before tax7.298.849.27
Net profit5.568.126.90

Quest Laboratories profit and loss

Full years to March, FY21 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY21FY22FY23FY24FY25FY26
Sales30596283103.91111.82
Expenses2953546787.9393.58
Operating profit1681615.9818.24
OPM4.7%11.0%13.0%19.0%15.4%16.3%
Other income00004.242.54
Interest00110.911.85
Depreciation00110.640.82
Exceptional and other items··1···
Profit before tax1671418.6818.11
Tax rate0.0%33.3%28.6%28.6%27.4%17.1%
Net profit1451013.5715.02
EPS ₹···8.458.289.16
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%

The years to FY24 come rounded to the nearest crore in the source.

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Quest Laboratories profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%10%20%30%FY21: 4.7%4.7%FY21FY22: 11.0%11.0%FY22FY23: 13.0%13.0%FY23FY24: 19.0%19.0%FY24FY25: 15.4%15.4%FY25FY26: 16.3%16.3%FY26
Per cent
FY21FY22FY23FY24FY25FY26
Operating margin4.7%11.0%13.0%19.0%15.4%16.3%
Tax rate0.0%33.3%28.6%28.6%27.4%17.1%
ROCE·54.5%50.0%56.6%26.8%18.4%
ROE·50.0%40.0%45.5%24.5%16.8%
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%

Quest Laboratories debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown. It cut its borrowings last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. Customers take about as long to pay as they did in FY24.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
0255075100Net worth, FY21: 6 ₹ cr6Borrowings, FY21: 3 ₹ cr3FY21Net worth, FY22: 10 ₹ cr10Borrowings, FY22: 3 ₹ cr3FY22Net worth, FY23: 15 ₹ cr15Borrowings, FY23: 4 ₹ cr4FY23Net worth, FY24: 29 ₹ cr29Borrowings, FY24: 5 ₹ cr5FY24Net worth, FY25: 81.8 ₹ cr81.8Borrowings, FY25: 30.3 ₹ cr30.3FY25Net worth, FY26: 96.8 ₹ cr96.8Borrowings, FY26: 7.9 ₹ cr7.9FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-30-20-1001020Cash from the business, FY21: 1 ₹ cr1Net profit, FY21: 1 ₹ cr1FY21Cash from the business, FY22: 3 ₹ cr3Net profit, FY22: 4 ₹ cr4FY22Cash from the business, FY23: 4 ₹ cr4Net profit, FY23: 5 ₹ cr5FY23Cash from the business, FY24: 3 ₹ cr3Net profit, FY24: 10 ₹ cr10FY24Cash from the business, FY25: -23.5 ₹ cr-23.5Net profit, FY25: 13.6 ₹ cr13.6FY25Cash from the business, FY26: -10.7 ₹ cr-10.7Net profit, FY26: 15 ₹ cr15FY26

Bars below the line are cash going out.

Quest Laboratories balance sheet

At each 31 March · ₹ crore

₹ crore
FY21FY22FY23FY24FY25FY26
Equity capital1111216.3916.39
Reserves59141765.4280.43
Net worth610152981.8096.82
Borrowings334530.257.89
Other liabilities92228279.606.44
Total liabilities18354761121.65111.15
Fixed assets67101011.7914.81
Capital work in progress000001.46
Investments000749.2312.18
Other assets1228374460.6382.70
Receivables····30.0336.21
Inventory····21.3738.62
Cash····0.110.10
Trade payables····5.735.61

Quest Laboratories cash flow

₹ crore

₹ crore
FY21FY22FY23FY24FY25FY26
Cash from operations1343-23.48-10.72
Cash from investing-1-2-4-5-43.9734.94
Cash from financing000267.42-24.23
Net cash flow0100-0.03-0.01
Capital spending····3.475.25

Working capital

Days

Days
FY21FY22FY23FY24FY25FY26
Debtor days110135118108105118
Inventory days1299711399163
Days payable1191402151442624
Cash conversion cycle34177178258
Working capital days914275872218

Quest Laboratories peers and competitors

Listed SME companies in the same industry

By sales, Quest Laboratories is number 13 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories1469.71121516.3%0.08
KRM Ayurveda57328.61022030.0%0.00
Sotac Pharmaceuticals10017.31015.817.7%0.64
Accretion Pharmaceuticals21522.289.69.716.7%0.23
Walpar Nutritions259.978.82.58.5%0.89
Median of the 10 others15819.81236.112.8%0.48

Quest Laboratories shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company, a little more than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has come down.

Promoters
66.78%
+0.95 pts since May 24
Foreign investors (FIIs)
0.61%
-3.99 pts since May 24
Indian institutions (DIIs)
2.04%
-5.06 pts since May 24
HNIs (over ₹2 lakh each)
15.48%
+8.75 pts since May 24
Small holders (up to ₹2 lakh)
11.51%
-0.36 pts since May 24
Companies and others
3.58%
-0.29 pts since May 24
Number of shareholders
911
1,732 in May 24

Quest Laboratories shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

May 24Sep 24Dec 24Mar 25Sep 25Dec 25Mar 26
Promoters65.83%65.83%65.83%66.21%66.78%66.78%66.78%
Foreign investors (FIIs)4.60%0.74%1.31%0.95%0.93%0.61%0.61%
Indian institutions (DIIs)7.10%4.44%4.86%2.07%1.39%1.37%2.04%
HNIs (over ₹2 lakh each)6.73%13.22%11.54%12.09%11.95%15.32%15.48%
Small holders (up to ₹2 lakh)11.87%9.90%10.56%12.26%13.55%13.04%11.51%
Companies and others3.87%5.87%5.90%6.42%5.40%2.88%3.58%
Number of shareholders1,7328578971,0011,0841,017911

The named holders are at 31 March 2026, beside 31 Dec 2025, each under the group the pattern files them in.

Quest Laboratories study: the business from its own documents

Read from 7 of the company's own documents

Quest Laboratories so far

From the company's own record

  1. 23 May 2024Listed on NSE Emerge at ₹97
  2. 29 Sept 2026Order worth ₹10.71 cr
  3. 31 March 2026Promoters at 66.78%
  4. 1 May 2026Highest close since listing, ₹151.65

Quest Laboratories key facts from the filings

Each figure with the document it comes from

FY26 sales
₹111.8 cr
Revenue from operations, up 7.6% from ₹104.0 cr; profit after tax was ₹14.9 cr, helped by lower tax.Annual report FY26, p.15
Government business
62.5%
Share of FY25 revenue from government institutions; the rest came from private buyers.Investor presentation, Jul 2025, p.11
Tablets
₹66.7 cr
FY25 tablet sales, about two thirds of revenue; syrups, suspensions, oral salts and ointments make up the rest.Investor presentation, Jul 2025, p.11
Tablet capacity used
77.9%
Use of the 360 crore tablets a year capacity in FY25; syrups ran at 87.4% and oral salts at 84.4%.Investor presentation, Jul 2025, p.11
Order book
₹39.7 cr
Orders in hand on 28 September 2026, including ₹10.7 cr of export orders and ₹16.9 cr of domestic sales booked for the third quarter.Exchange announcement, 28 Sep 2026
Show 5 more facts
Stock of goods
₹38.6 cr
Inventory at March 2026, up from ₹21.4 cr a year earlier while sales rose less than a tenth.Annual report FY26, p.55
Money owed by customers
₹36.2 cr
Trade receivables at March 2026, up from ₹30.0 cr.Annual report FY26, p.55
Short term borrowings
₹7.0 cr
At March 2026, down from ₹28.9 cr, as the company drew down its short term investments to ₹12.2 cr from ₹49.2 cr.Annual report FY26, p.55 and p.56
Products licensed
1,300+
Formulations the company holds licences for; it makes 250 to 300 of them in a year, depending on demand.Investor presentation, Jul 2025, p.4 and p.16
Promoter holding
66.78%
Held by the promoter group at March 2026, with none pledged.Shareholding pattern, March 2026

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company told the exchange on 28 September 2026 that it had ₹39.7 cr of orders in hand, with export orders and domestic sales already booked for the third quarter. It says it is building an injectable section with oncology, ampoule, vial and dry injection lines for domestic and export markets, and is registering cardiovascular and diabetes medicines in Myanmar. From FY27 it will report results every half year instead of every quarter.

₹39.7 crOrder book28 September 2026
₹10.7 crExport orders for the third quarterFY27
₹1.5 crCapital work in progressMarch 2026
What management saidWhenWhat happened
Domestic sales growth of 30%Jul 2025 presentationTotal revenue from operations grew 7.6% in FY26

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Quest Laboratories earns its money making cheap, common medicines in large volumes, mostly for government programmes that hand them out free.

Its weak spots are that tender prices are set by bidding, and a lot of money gets tied up in stock and in what government buyers owe.

WatchCan it set its own prices?Most sales are won in government tenders, where price is a main test, and the company itself names pricing pressure from competition as a risk.
The evidence. Bids are judged on price, qualifications, experience and past performance; the annual report says more competition may affect pricing and market share.Offer document, p.161; Annual report FY26, p.41
AverageHow strong is it against rivals?It has a wide licensed range and its own testing laboratory, but it makes common generics that many others also make.
The evidence. The offer document says many competitors have far greater financial resources and research strength, and that it competes on quality, brand image, price and reliability.Offer document, p.162
WatchWho are its customers?Government health buyers bring most of the money, and sales lean heavily on a few states.
The evidence. Government institutions were 62.5% of FY25 revenue; in the nine months to December 2023 Uttar Pradesh and Madhya Pradesh made up about 95% of sales.Investor presentation, Jul 2025, p.11; Offer document, p.137
WatchDoes it need a lot of money?Yes for running the business: stock and receivables grew much faster than sales in FY26.
The evidence. Inventory rose to ₹38.6 cr from ₹21.4 cr and receivables to ₹36.2 cr from ₹30.0 cr while revenue grew 7.6%.Annual report FY26, p.15 and p.55
AverageCan it keep finding new work?It has a running order book, a new export business and new lines being built, but growth slowed in FY26.
The evidence. Orders in hand were ₹39.7 cr on 28 September 2026, including ₹10.7 cr of exports; revenue grew 7.6% in FY26.Exchange announcement, 28 Sep 2026; Annual report FY26, p.15
AverageDo good and bad years swing a lot?Demand for basic medicines is steady, but the timing and size of government tenders can move sales from year to year.
The evidence. Government share of sales rose from 18% in FY21 to 67% in the nine months to December 2023, and the mix between states changed sharply from year to year.Offer document, p.136 and p.137

Who runs Quest Laboratories?

Promoters, directors and officers; tap a name for the background

AKAnil Kumar SabarwalPromoter, Chairman and Managing Director

A director since June 1998 with over 25 years in the company; holds a secondary school certificate from Kendriya Vidyalaya, Sriganga Nagar. Responsible for strategy, overall management, new capacity, new products and markets in India and abroad. FY26 pay was ₹0.72 cr.

Offer document, p.179 and p.181; Annual report FY26, p.71
TSTejaswini SabarwalPromoter and Whole-Time Director

A Bachelor of Pharmacy from Swami Vivekanand College of Pharmacy, Indore (2017), on the board since March 2021; looks after planning and development of the quality control section. The offer document records Tejaswini Sabarwal and Anil Kumar Sabarwal as husband and wife. FY26 pay was ₹0.30 cr.

Offer document, p.181 and p.182; Annual report FY26, p.71
VSVinayak SabarwalWhole-Time Director

A BA in Journalism and Mass Communication from Devi Ahilya University, Indore (2021), studying for a B.Pharm; about three years in various areas of the business. FY26 pay was ₹0.30 cr.

Investor presentation, Jul 2025, p.12; Annual report FY26, p.3 and p.71
USUmendra SutharWhole-Time Director

A B.Sc. from Devi Ahilya University, Indore (1991), with over 22 years in pharmaceutical production.

Investor presentation, Jul 2025, p.12; Annual report FY26, p.3 and p.70
GKGautam KothariIndependent Director

A fellow chartered accountant with an M.Com, an MA in Sociology and a law degree, and more than 44 years in accounting and finance; also a director of Porwal Auto Components.

Offer document, p.180 and p.181
ARAmit Ramesh ChandakIndependent Director

A B.Com from Amravati University and a fellow chartered accountant, with 14 years in taxation, financial reporting, debt syndication and compliance.

Offer document, p.182
BLBasant Lal MenghwaniIndependent Director

A Bachelor of Pharmacy from the University of Indore (1977), with around 30 years in the pharmaceutical industry.

Offer document, p.182
RSRamkrishna SharmaChief Financial Officer

An MBA in finance from Sikkim Manipal University and a master's in personnel management from Pune University, with 20 years of experience; oversees finance and accounts.

Investor presentation, Jul 2025, p.12
ATAyushi TaunkCompany Secretary and Compliance Officer

Appointed from 3 September 2025 after Surabhi Gupta resigned.

Annual report FY26, p.17

Quest Laboratories latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹63 cr (+3%), net profit ₹6.9 cr (+24%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters unchanged at 66.78%.
  • 29 Sept 2026: order worth ₹10.71 cr announced.

Quest Laboratories annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Quest Laboratories share split, bonus and dividends

From the corporate actions the company announces on the exchange

No share split, bonus issue or dividend is on record since listing.

Checks we ran on Quest Laboratories' data · 9

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,63,87,200 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • ✓Earnings per share moves in line with profit across the years shown.
  • ✓Revenue and profit are reported for every year shown, FY21 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Quest Laboratories

What does Quest Laboratories do?

Quest Laboratories makes everyday generic medicines such as tablets, syrups, oral rehydration salts and ointments at its plant in Pithampur, Madhya Pradesh, mostly for government health programmes. Its shares trade on NSE Emerge.

What is the share price of Quest Laboratories?

₹89.1 at the close on 18 Nov 2026, from the exchange's daily figures.

What is the market cap of Quest Laboratories?

₹146 cr at the close on 18 Nov 2026, on 1,63,87,200 shares.

What is the P/E of Quest Laboratories?

9.7 times FY26 profit at the close on 18 Nov 2026 (our arithmetic).

What are Quest Laboratories' revenue and profit?

Revenue ₹112 cr and profit after tax ₹15 cr in FY26.

Who are the promoters of Quest Laboratories?

Anil Kumar Sabarwal, Tejaswini Sabarwal; promoters held 66.78% at 31 March 2026.

What was the IPO price of Quest Laboratories?

₹97 a share; it listed on 23 May 2024.

What is Quest Laboratories' website?

www.questlabltd.com

More SME companies like Quest Laboratories

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2024 →

Built from 3 investor presentations, 2 annual reports, 1 offer document, 1 result filing, 80 exchange announcements, 7 shareholding patterns and 6 years of reported results. Every figure carries its source; where the documents are silent, the page says so.